Author:
Armstrong Andrew J.,Clarke Noel,Oya Mototsugu,Procopio Giuseppe,de Menezes Juliana,Guedes João Daniel,Ghatalia Pooja,Nolè Franco,Din Omar,Spiegelhalder Philipp,Mincik Ivan,van Alphen Robbert,Lumen Nicolaas,Hosius Christian,Zhou Diansong,Barker Laura,Dujka Melanie,Saad Fred
Subject
Urology,Radiology, Nuclear Medicine and imaging,Oncology,Surgery
Reference17 articles.
1. Abiraterone and olaparib for metastatic castration-resistant prostate cancer;Clarke;NEJM Evid,2022
2. US Food and Drug Administration. Highlights of prescribing information: LYNPARZA® (olaparib) tablets, for oral use. Updated: May 2023. www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf.
3. Janssen. Highlights of prescribing information: ZYTIGA® (abiraterone acetate) tablets. Updated August 2021. www.janssenlabels.com/package-insert/product-monograph/prescribing-information/ZYTIGA-pi.pdf.
4. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer;Li;Nature,2015
5. A PK/PD study of Delta-4 abiraterone metabolite in metastatic castration-resistant prostate cancer patients;Blanchet;Pharmacol Res,2018
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献